Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTENTION: Tivantinib plus erlotinib vs placebo plus erlotinib in previously treated EGFR wild-type non-squamous NSCLC
jRCT2080221484Phase 3
- Sponsor
- Kyowa Kirin
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing tivantinib + erlotinib with placebo + erlotinib (2 arms).
02
Drugs
tivantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080221484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221484.